Economic benefits of amlodipine treatment in patients with coronary artery disease

PharmacoEconomics

Volumn 20, Issue 8, 2002, Pages 553-563

  Casciano, R ^a   Doyle, J J ^a   Chen, J ^b   Arikian, S ^a   Casciano, J ^a   Kugel, H ^a   Arocho, R ^c  

^a Analytica Group   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PHARMACOECONOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0036323977     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220080-00005     Document Type: Article

References (12)

1. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass grafting
2. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease
3. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease
4. Primary angioplasty in the treatment of acute myocardial infarction
5. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events
6. Markov models in medical decision making: A practical guide
7. Cost effectiveness of coronary heart disease prevention strategies in adults